Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "SPARC Announces Sale of Priority Review Voucher for US $195 million".
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SPARC has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for US$195 million. The PRV was granted by the US FDA upon approval of Sezaby, a treatment for neonatal seizures. The company stated the sale will accelerate development of pipeline assets and strengthen its external innovation strategy. The transaction is subject to customary closing conditions, including expiration of the Hart-Scott Rodino Antitrust waiting period. Stifel acted as exclusive financial advisor to SPARC. There is no shareholding in the buyer and the transaction is not a related party transaction.
This is a significant one-time cash inflow that will bolster SPARC's balance sheet and fund pipeline development. While positive for liquidity, it represents monetizing a one-time regulatory asset rather than recurring business income.